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Idiopathic hypercalciuria associated with hyperreninemia and high
urinary prostaglandin E. A patient with idiopathic hypercalciuria and
some features suggestive of Bartter syndrome is reported. Excessive
urinary prostaglandin E (PGE) excretion and renal calcium leak were
documented in this child. Treatment with aspirin and indomethacin re-
duced urinary PGE excretion and was associated with a decrease in
daily calcium excretion. At the lowest levels of urinary POE, the renal
calcium leak was no longer evident although mild hypercalciuria per-
sisted. These results suggest that POE may play a role in some cases
of idiopathic hypercalciuria.
Hypercalciurie idiopathique associée a une hyperréninémie et a des
prostaglandines E urinaires élevées. On rapporte un malade porteur
d'une hypercalciurie idiopathique et de quelques caractéristiques
suggdrant un syndrome de Bartter. Une excretion excessive de pros-
taglandines E (POE) urinaires et une fuite rdnale calcique ont ëté
documentées chez cet enfant. Un traitement par de l'aspirine et de
l'indométhacine a réduit l'excrétion urinaire de PGE et s'est
accompagne d'une diminution de l'excrétion calciquejournaliere. Pour
les plus faibles niveaux de PGE urinaires, Ia fuite rénale calcique
n'était plus évidente bien que persiste une hypercalciurie modérCe. Ces
résultats suggerent que les POE pourraient jouer un role dans certains
cas d'hypercalciurie idiopathique.
Idiopathic hypercalciuria is a common occurrence in the
healthy adult population [1] and is found in 40 to 60% of pa-
tients with recurrent calcium nephrolithiasis [1—3]. The dis-
order appears to have a genetic basis [1] and is thought to have
a similar prevalence in children [41. The pathogenesis of hyper-
calciuria is still controversial [2, 5—71 although two major
mechanisms emerge [81. Some patients have a primary defect
of intestinal hyperabsorption of calcium [8—9], while in others,
the defect is felt to be an impairment of renal tubular calcium
reabsorption [6, 8, 9]. Renal phosphate wasting has been iden-
tified in some patients and suggested as an etiologic factor in
idiopathic hypercalciuria [2, 7, 10, 11], although some authors
consider it to be simply a subset [121. Recent evidence also
suggests a proximal tubular defect in salt and water reabsorp-
tion [2, 13] which has been offered as a cause of phosphate
wasting and hypercalciuria [2].
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In children, idiopathic hypercalciuria has been less well char-
acterized but seems to occur in a sizable percentage of healthy
children and may be associated with a variety of urinary tract
symptoms [4, 14]. Stapleton et al [151 studied a group of 21 chil-
dren with calcium urolithiasis using oral calcium-loading stud-
ies and found that 80% had idiopathic hypercalciuria. Of these
patients, 82% had renal hypercalciuria and 18% had absorptive
hypercalciuria. The presence of phosphate wasting with absorp-
tive hypercalciuria has also been reported in children [16]. Uro-
lithiasis, however, is not the only abnormality associated with
idiopathic hypercalciuria in children [14, 17]. Royer et al [17]
reported ten children with hypercalciuria associated with neph-
rocalcinosis, growth failure, polydipsia, polyuria, defective re-
nal concentrating capacity, and osteoporosis. Subsequently,
other children with hypercalciuria and nephrocalcinosis or rick-
ets have been reported [14, 18—211. Many of the latter have had
features suggestive of Bartter syndrome associated with mul-
tiple tubular defects [18—22].
We describe a patient with idiopathic hypercalciuria asso-
ciated with polyuria, polydipsia, hyperreninemia, and nephro-
calcinosis. A detailed metabolic evaluation of this child sug-
gested the presence of a prostaglandin-mediated defect in re-
nal tubular calcium reabsorption.
Case report
This patient exhibited symptoms at 19 months of age when
his mother noted excessive thirst. Fluid intake was approxi-
mately 2 liters/day; a random urinalysis was normal (specific
gravity: 1.004). When 4 years old the patient was recognized
to have growth failure, polydipsia now approaching 4 liters
each day, and enuresis. Urine osmolality was 365 mOsm/kg
H20 after dehydration and the administration of 5 U of aque-
ous vasopressin. Nephrocalcinosis was subsequently demon-
strated without evidence of primary hyperparathyroidism, vi-
tamin D intoxication, renal tubular acidosis, hyperoxaluria, or
Fanconi syndrome. Twenty-four-hour urinary calcium excre-
tion was 9.6 mg/kg (normal < 4 mg/kg) and was unchanged fol-
lowing 12 hr of fasting. A diagnosis of idiopathic renal hyper-
calciuria was made, and the patient was started on a thiazide
diuretic in addition to a diet low in calcium and sodium. Cal-
cium excretion tended to decrease on this regimen but was
variable (6.6 to 10.5 mg/kg). In addition, this therapy was as-
sociated with hypokalemia (2.3 to 3.0 mEq/liter) despite oral
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potassium chloride supplementation of up to 120 mEq/day (7.5
mEq/kg). Because of the ineffectiveness of the thiazide therapy
and its associated hypokalemia, the diuretic and potassium
chloride supplementation was discontinued Subsequently,
urine calcium increased (20 to 22 mg/kg/day) as did urine vol-
ume (2250 to 3000 cc/day) and serum potassium (3.2 to 3.9
mEq/liter).
At 6 years of age, the child was evaluated further to better
characterize the hypercalciuria. A modified protocol based on
the studies of Pak et a! [9] was utilized. Following stabilization
on a low calcium diet, fasting calcium excretion was 0.7 mg/mg
creatinine (normal in children < 0.2); parathormone (PTH) was
120 dEq/ml (Nichols Institute, Los Angeles, California; nor-
mal < 100) and urinary cyclic AMP was 18.1 moles/g creati-
nine (normal < 7). After a 500-mg calcium meal, calcium ex-
cretion increased to 0.92 mg/mg creatinine (normal in children
< 0.27) and urinary cyclic AMP decreased to 12.6 imoles/g
creatinine. In addition, the child had an elevated supine plasma
renin activity (PRA) (46 ng angiotensin I/mllhr; normal < 5.5),
urinary aldosterone excretion (21 tg/day; normal < 15), and in-
sensitivity to the pressor effects of angiotensin II, requiring 60
gIkg/min for a 20-mm increase in diastolic BP. A blood vol-
ume determination and a renal biopsy were normal; there was
no evidence of juxtaglomerular cell hyperplasia. The patient
was considered to be a variant of Bartter syndrome demon-
strating idiopathic renal hypercalciuria and nephrocalcinosis
[19, 20, 22].
A trial of salicylate therapy was begun. The polyuria de-
creased, enuresis disappeared, and PRA returned to normal.
These findings were associated with a decrease in urinary cal-
cium excretion. When salicylates were discontinued, the symp-
toms of polyuria recurred along with the hypercalciuria. Based
on this experience, a protocol was designed to assess the ef-
fects of prostaglandin inhibition using aspirin and indometh-
acm, two chemically dissimilar inhibitors of cyclo-oxygenase
[23].
Methods
To initiate the study, all previous therapy as well as diet re-
strictions were withdrawn. Two weeks later, duplicate 24-hr
urine collections were obtained at home; these samples were
designated as baseline. The child was then placed on a diet
consisting of 1900 calories, 400 mg calcium, 800 mg phospho-
rus, 80 mEq sodium, 60 mEq potassium, 75 g protein, and ad
lib fluid intake; compliance was monitored at home using a diet
diary. Following a 2-week period of stabilization on this diet,
the study protocol was initiated. This protocol consisted of
four identical 6-day evaluations in the clinical research center
at the University of Minnesota Hospitals. The first study (des-
ignated diet modified or period 1) was done while the child was
not receiving therapy. The second and third studies, desig-
nated periods 2 and 3, were done while the child received 60
and 100 mg/kg of aspirin and the fourth during therapy with 3
mg/kg of indomethacin (period 4). Each evaluation was sepa-
rated by at least 2 weeks to allow for adequate stabilization on
drug therapy.
During each of the four study periods, the following se-
quence of investigation was used. The day 1 allowed for ac-
climatization to the Clinical Research Center as well as moni-
toring of dietary intake. On days 2 and 3, 24-hr urine collec-
tions and blood samples were obtained. All of the 24-hr sam-
ples were analyzed for electrolytes, creatinine, calcium, phos-
phorus, magnesium, citrate, oxalate, uric acid, PGE, and uri-
nary saturation kinetics were done. The blood samples were
analyzed for electrolytes, bicarbonate, creatinine, ionized cal-
cium, phosphorus, 25-hydroxyvitamin D (25-OHD), 1,25-
dihydroxyvitamin D [1,25 (OH)2D] as well as supine and 2-hr
upright PRA.
The maximal urinary concentrating capacity was assessed on
day 4 [24] of each study period. With no preceding fluid restric-
tion, the child was given 20 tg of DDAVP intranasally. One
hour later, he was instructed to empty his bladder by double
voiding; subsequently, two 2-hr urine collections were ob-
tained for osmolality. The correlation between maximal urine
osmolality obtained by this method as compared to prolonged
dehydration or dehydration and pitressin is excellent [241. Fol-
lowing this study and the evening meal, the patient was fasted
but allowed free access to distilled water. The following morn-
ing (day 5), an oral calcium-loading study was performed [9,
25]. The protocol utilized was identical to that described by
Pak et al [9], except that the oral calcium load consisted of 250
calories, 650 mg calcium, 15 mEq sodium, and 75 mg phospho-
rus. On day 6, tubular function was evaluated during maximal
free-water diuresis using accepted clearance methods [26, 27].
To suppress endogenous vasopressin, an oral load of 900 ml (30
ml/kg) of water was given over 1 hr followed by 20 mI/kg/hr.
When urine volume was stable at a value greater than 8 mllmin,
two I-hr urine collections were obtained along with midpoint
blood samples.
Four age-matched normal children were used as control sub-
jects for baseline urinary excretion data only. These children
were not subjected to diet modification or therapy prior to ob-
taining a single 24-hr urine collection for the assessment of
PGE, calcium, and sodium excretion. This study was ap-
proved by the committee on the use of Human Subjects in Re-
search at the University of Minnesota and informed written
consent was obtained.
Routine blood and urine chemistries were analyzed accord-
ing to standard techniques in the University of Minnesota Hos-
pital Clinical Laboratory. Ionized calcium (normal 4.4 to 4.8
mg/dl) was measured by an ion selective electrode (Orion®,
Cambridge, Massachusetts). Oxalate determinations were done
using the technique of Hodgkinson and Williams [28]; urinary
citrate was measured using the citrate lyase method [29]. Uri-
nary cyclic AMP (normal < 7 jmoles/g creatinine), PTH (Ni-
chols Institute; normal < 100 ilEq/ml), PRA (normal < 5.5 ng
angiotensin I/mi/hr [supine]; <7.8 [upright]) and PGE were all
measured by radioimmunoassay using standard techniques
[30.—33]. 1,25 (OH)2D (adult normal, 16 to 46 pg/mi; children's
normals, 11 to 111 pg/ml [34]) and 25-OHD (normal 20 to 90
ng/ml) were measured using competitive binding assays, ac-
cording to the methods of Malion et a! (Roche Clinical Labs.,
Raritan, New Jersey) [35] and Belsey, DeLuca, and Potts [36].
The concentration product ratios and formation product ra-
tios for brushite and calcium oxalate monohydrate were cal-
culated using a modification of the technique of Pak, Ohata,
and Holt [37] and Pak et al [38]. Tubular reabsorption of phos-
phate (TRP) was calculated using the standard formula and the
renal threshold phosphate concentration (TMPO4/GFR) was
derived using the nomogram of Walton and Bijvoet [39].
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Table 1. Baseline daily urinary excretion in the patient and four
normal children
Normal children
(mean SD) PatientA B C D
Volume, mi/kg 23.1 28.9 21.7 43.6 (29.3 10.0) l12.5
Calcium, mg/kg 1.1 2.4 1.8 1.8 (1.8 0.5) 17.2'
PGE, ng/kg 6.4 5.6 4.4 5.8 (5.6 0.8) 24.9
Sodium, mEq/kg 1.9 3.5 2.6 5.5 (3.4 1.6) 5.8
A value outside the 99% confidence limits was established for
normal subjects.
Statistical comparisons between urinary excretion in the
controls and the patient were done by establishing confidence
limits for each parameter in the normal children. Comparisons
between Baseline and study periods 1 through 4 were done
using one-way analysis of variance followed by Newman-Keuls
multiple comparisons [40]. Linear regressions were calculated
using the least squares method.
Results
Baseline daily urinary excretion in this patient and four nor-
mal children on a free choice diet is shown in Table 1. When
compared with normal children, the patient had a tenfold in-
crease in calcium excretion along with a fourfold increase in
urine volume and PGE excretion. Sodium excretion, although
higher in the patient, was not significntly different from control
subjects.
Table 2 details daily urinary excretion as well as renal func-
tion on days 2 and 3 during each study. In response to diet
modification (period 1), the patient demonstrated a significant
reduction in urinary sodium, chloride, phosphorus and cal-
cium (P < 0.05) although absolute calcium excretion was still
elevated. Coincident with these changes, urine volume de-
creased (P > 0.1) and PGE excretion rose (P < 0.05). Citrate
excretion which had been in the low normal range [41] during
baseline increased significantly (P < 0.05); there was no fur-
ther change in citrate, sodium, chloride, or phosphorus excre-
tion during the remainder of the study. Potassium, mag-
nesium, uric acid, and oxalate excretion were all normal at
baseline (data not shown) and were unchanged during the other
periods. During low-dose aspirin therapy (period 2), the saucy-
late level was 16 mg/dl; there was a moderate reduction in urine
volume (P > 0.1) as well as a significant reduction in PGE and
calcium excretion (P < 0.05). Increasing the aspirin dose to 100
mg/kg produced a salicylate level of 31 mg/dl without signs of
salicylate intoxication (period 3). As shown, this was associ-
ated with a further reduction in urine volume, calcium, and
PGE excretion. Urine volume and PGE excretion were re-
duced as compared to period I (P < 0.05), although the
changes were not significant between periods 2 and 3. Calcium
excretion, however, was reduced by increasing the dose of as-
pirin (P < 0.05). There was a further reduction in urine vol-
ume and PGE excretion with near normalization of daily uri-
nary calcium excretion following treatment with indomethacin
(period 4). Positive correlations were found between urine vol-
ume, calcium, and PGE excretion during periods 1 through 4.
The correlation coefficients between PGE and calcium excre-
tion (r = 0.84; P < 0.01), PGE excretion and urine volume (r
= 0.93; P < 0.001) as well as calcium excretion and urine vol-
ume (r 0.98; P < 0.001) were all significant.
Serum chemistries were normal during periods I to 4 except
for a mild depression of ionized calcium during periods 1 (4.3
mg!dl) and 4 (4.2 mg/dl). There was a slight increase in 25 OHD
that was present throughout the study. It is important to note
that there was no significant (P > 0.3) change in GFR (Table
2) or in the filtered load of calcium during the treatment peri-
ods which might explain the reduction in calcium excretion.
Figure 1 depicts supine and upright PRA contrasted with
daily urinary PGE excretion during periods 1 through 4. Su-
pine and upright PRA and PGE excretion were elevated in pe-
riod 1 and were markedly reduced during the treatment peri-
ods. The correlation between PRA and PGE excretion was
nearly perfect (PGE and supine PRA, r = 0.986, P < 0.02;
PGE and upright PRA, r = 0.997, P < 0.01).
Maximum urinary concentrating capacity after DDAVP ad-
ministration is shown in relation to daily urine volume and PGE
excretion in each of the four periods in Table 3. Urine volume
and PGE excretion decreased during the study associated with
aspirin and indomethacin therapy. Coincident with this, maxi-
mum concentrating capacity increased although not into the
normal range. Inverse correlations were found between PGE
excretion and maximal concentrating capacity (r =
—0.87; P
<0.01) and between daily urine volume and maximum concen-
trating capacity (r = —0.995; P < 0.01).
Table 4 provides the data obtained during the calcium-load-
ing study in each period. Fasting urinary calcium/creatinine ra-
tios were high during periods 1 and 2 and were normalized dur-
ing the high-dose aspirin and indomethacin periods. Following
the calcium meal, calcium excretion was high in periods 1 and
2 but fell to normal levels in periods 3 and 4 [25]. PTH was el-
evated in period 1 but not during therapy. Fasting urinary cy-
clic AMP values were normal and decreased after calcium
loading in all periods. Urinary cyclic AMP did not correlate
with circulating PTH levels (r =
—0.04). TRP varied from 93
to 99% and TMPO4/GFR ranged from 5.4 to 7.4 mg/dl during
the study (data not shown); all of these values are normal [42].
The results obtained during maximal free-water clearance
are given in Table 5. During period 1, the patient was able to
produce a maximally dilute urine (41 mOsm/kg). Distal chlo-
ride delivery (Cc1 + CH,o), reflecting proximal tubular func-
tion, was normal as was distal tubular function estimated from
the distal fractional reabsorption of chloride (CH2O/CH2o + Cc1)
[26, 27]. These findings are not consistent with the generally
recognized defect in chloride reabsorption seen in Bartter syn-
drome [20, 22, 26, 27]. Tubular function and GFR were not ap-
preciably changed by either aspirin or indomethacin.
Urinary saturation kinetics were measured during each pe-
riod and demonstrated that at baseline, the patient's urine was
mildly supersaturated with calcium oxalate and brushite. Dur-
ing the study, as both calcium excretion and urine volume de-
creased, the urine became more supersaturated with calcium
oxalate while brushite saturation was not appreciably altered.
The formation product ratios, which reflect the limit of meta-
stability, were normal during baseline and decreased slightly
during the study but not to abnormal values [43].
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Table 2. Renal function and daily urinary excretiona
Study period
1 2 3 4
Baseline Diet modified Low-dose aspirin High-dose aspirin Indomethacin
Volume, mI/kg 112.5 90.3 63.5 50.7' 42b
Calcium, mg/kg 17.2 10.5 8.1" 5.l 4.lc
Prostaglandin E, ng/kg 24.9 71.3 6.7" 4.1" 2.8"
Sodium, mEq 174 82 74 77 76
Chloride, mEq 144 61 64 65 67
Phosphorus, mg 994 515 672 653 494
Citrate, mmoles 0.48 1.49 1.96 1.92 1.8
Creatinine clearance, mi/minll.73 m2 ND 108 108 106 101
Abbreviation: ND, creatinine clearance not done during Baseline; clearance values are not different during periods 1 to 4.
a All values except urine volume during period 1 are significantly (P < 0.05) different from Baseline.
b P < 0.05 compared to Baseline and Diet modified.
P < 0.05 compared to Baseline, Diet modified, and Low-dose aspirin.
Study period
Fig. 1. Comparison of supine (U) and upright (LI) plasma renin activ-
ity (PRA) with daily prostaglandin E (PGE, I—•) excretion while diet
modified (period 1) or following treatment with aspirin (periods 2 and
3) or indomethacin (period 4). PRA in children (mean SD) is 2.7
1.4 ng Al/mi/hr (supine) and 4.0 1.9 (upright). Al represents angi-
otension I.
Discussion
The patient we report has idiopathic hypercalciuria, defined
by calcium excretion greater than 4 mg/kg/day on a normal cal-
cium diet in the absence of hypercalcemia or other recogniz-
able causes of hypercalciuria [6, 7, 14]. In addition, this child
was documented to have many features suggestive of Bartter
syndrome, that is, growth failure in infancy, polyuria, elevated
PRA and aldosterone excretion, insensitivity to the effects of
angiotensin II, and increased amounts of urinary PGE [20, 22,
26]. He did not, however, demonstrate spontaneous potassium
wasting with hypokaleniia, alkalosis, or a defect in proximal or
distal tubular sodium or chloride handling (Table 4) usually
seen in these patients [20, 22, 26, 27]. Similar patients with
hypercalciuria associated with Bartter-like syndromes have
been reported [17—21], although these patients generally had
80 hypokalemia and features suggestive of renal tubular acidosis
or Fanconi syndrome which were not present in our patient.
The initial calcium-loading studies (Table 4) performed dur-
ing period I when the patient was on a restricted diet demon-
strated renal leak hypercalciuria as defined by Pak et al in
adults [3, 9] and by Stapleton et al in children [25]. It is of in-
terest that in the face of an elevated PTH, normal serum phos-
phorus and decreased ionized calcium, that the level of 1,25-
OH2D was not strikingly elevated [34, 44, 45] and that the TRP,
TMPO4/GFR and urinary cyclic AMP were normal. The latter
findings may be secondary to the excessive PGE excretion,
since Dominquez et al [461 has shown that PGE2 infusions in-
hibit PTH-sensitive adenylate cyclase and phosphaturia in the
dog. Following treatment with low-dose aspirin (period 2), the
patient had a significant decrease in daily PGE excretion (Ta-
ble 2) into a range comparable to the normal children. In ad-
dition there was a reduction in daily calcium excretion, al-
though not into the normal range [6, 7, 14]. The "renal cal-
cium leak" improved and was associated with the normaliza-
tion of ionized calcium and PTH as well as a reduction in
l,25,OH2D. During periods 3 and 4, fasting hypercalciuria was
not present, suggesting that the renal tubular defect in calcium
excretion had been corrected following therapy with high-dose
aspirin and indomethacin. Urinary calcium excretion following
calcium-loading studies in periods 3 and 4 (Table 4) ap-
proached normal, demonstrating a marked reduction in the ab-
sorptive component of the hypercaiciuria. Since the patients of
Stapleton et al [25] were placed on a more restricted calcium
diet, we are not able to determine if calcium excretion is el-
evated following the calcium meal in these periods; the persist-
ence of elevated daily calcium excretion with normal fasting
excretion suggests that a mild absorptive component persists.
It must be acknowledged that 25-OHD levels were slightly el-
evated in all periods. This study was done during the summer
and early fall when 25-OHD levels are highest [47]. We would
not expect gastrointestinal calcium absorption to be aug-
mented by levels in this range [44, 45].
Although recent reports have suggested the presence of a
proximal tubular defect in salt and water handling in some pa-
tients with idiopathic hypercalciuria [2, 13], we did not iden-
tify such a defect in our patient or document any change in tu-
bular function following therapy (Table 5). Furthermore, our
a-
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Table 3. Concentrating capacity, urine volume and prostaglandin E excretion
Study period
The level of dietary sodium in our patient, even during periods
I to 4, would be unlikely to induce sodium depletion, es-
pecially in the absence of any abnormality in renal tubular so-
4 dium handling. In fact, dietary sodium was likely higher in our
h patient than in the normal children when his urinary PGE ex-Indomet acm
cretion was significantly higher (Table 1). It has also been sug-
269 gested recently that polyuria may result in increased urinary
67 PGE excretion [51]. However, in this patient, urinary PGE ex-
cretion increased (period 1) following dietary modification
2:7 while the urine volume decreased. This suggests that polyuria
1.4 was not an independent variable affecting PGE excretion.
9.7 While the mechanism leading to excessive PGE synthesis is
120
unclear, we feel that it is likely responsible for the elevation in
PRA and partially responsible for the polyuria and concentrat-
ing defect seen in this child [50, 52, 531. As mentioned previ-
ously, we do not feel volume contraction played a role in the
elevated PRA. It is possible that the elevation in PRA is a pri-
mary event or that it might be associated with the abnormality
in calcium handling [54, 55]. However, as prostaglandins stimu-
late renin release [53], it is more likely that the high PRA is sec-
ondary to the increased synthesis of PGE. The significant cor-
relation between PGE exretion and PRA (r = 0.99) would sup-
port this contention.
The most clinically impressive effect of aspirin or indometh-
acm on this patient was the improvement in polydipsia and loss
of enuresis following initiation of therapy. Although the pa-
tient has nephrocalcinosis and thus is not able to achieve maxi-
mal urinary concentration, we were able to improve the con-
centrating defect following therapy with either aspirin or indo-
methacin. A significant correlation was found between PGE ex-
cretion and daily urine volume as well as maximum concen-
trating capacity induced by DDAVP (Table 3). PGE has long
been recognized to influence renal water excretion, both by in-
hibiting arginine vasopressin induced hydro-osmotic water flow
and lowering renal medullary interstitial osmolality [50, 52, 56].
Previous in vivo studies in both humans and animals have doc-
umented this improvement in vasopressin-induced maximum
1 2 3
Diet modified Low-dose aspirin High-dose aspirin
4
Indomethacin
Urine volume, mi/kg/day 90.3 63.5 50.7
Prostaglandin E excretion, nglkg/day 71,3 6.7 4.1
Maximum concentrating capacity, mOsmlkg H20 325 400 447
Table 4. Parathormone, urinary calcium and cyclic AMP during fasting and calcium loading
Study period
1 2 3
Diet modified Low-dose aspirin High-dose aspirin
42
2.8
486
4
Indomethacin
Urinary calcium/creatinine, mg/mg FAST
LOAD
Parathormone, p.iEq/mi FAST
LOAD
Urinary cAMP, p.moieslg cr FAST
LOAD
Abbreviation: ND, Not done; cr, creatinine.
Table 5. Studies during maximal free-water clearance
0.46
0.88
141
119
4.6
4.1
0.37
0.47
79
88
5,9
5.2
0.13
0.22
78
74
4.9
Study period
0.07
0.27
ND
81
5.1
3.9
Diet
modified
3.3
2
Low-dose
aspirin
3
High-dose
aspirin
Sosm 267 269 275
UOSm 41 65 70
Va 10.0 12.5 11.0
CH2Oa
Cosma
8.5
1.5
9.5
3.0
8.2
2.8
C1' 1.2 2.0 1.5
DD1a 9.7 11.4 9.6
DR1 0.88 0.83 0.84C 116 112 106
Abbreviations: Sm, serum osniolality; U05, urine osmolality; V.
urine flow; CH2O, free Water clearance; Cosm, osmolar clearance; Cr1,
chloride clearance; DD1, distal delivery of chloride; DR1, distal
fractional reabsorption of chloride; Ccr, creatinine clearance (ml/min/
1.73 m2).
a The unit of measure used was mI/min/dI glomerular filtrate.
patient had a normal TRP, TMPO4/GFR and serum phospho-
rus which demonstrates that renal phosphorus wasting is not
present [2, 7, 10—12].
Therapy in any type of stone disease is usually directed to
decreasing the state of saturation of the urine for stone-form-
ing elements. Correcting the hypercalciuria in this patient was
associated with increasing saturation of the urine for calcium
oxalate. Because there was no increase in oxalate excretion,
this can best be explained by the simultaneous fall in urine vol-
ume. Therapy in this child would best consist of prostaglandin
inhibition and a high fluid intake.
We are uncertain about the primary stimulus for the exces-
sive POE excretion seen in our patient. Although there are a
large number of recognized mediators of renal PGE synthesis
[48], none seem immediately applicable in our patient. Severe
dietary sodium restriction leading to volume contraction is a
potent stimulus to renin release and PGE synthesis [49, 50].
Idiopathic hypercalciuria and prostaglandin E 181
concentrating capacity following prostaglandin synthesis inhi-
bition [56]. Although it is possible that the improvement in uri-
nary concentrating capacity may be related to the decrease in
renal calcium excretion [571, we feel that it is more likely due
to a decrease in urinary PGE.
Our report is the first to document improvement in idiopath-
ic hypercalciuria following treatment with indomethacin, The
previous reports noting improvement in hypercalciuria follow-
ing indomethacin have occurred in patients with renal tubular
acidosis or Bartter syndrome [19, 21, 58, 59]. In addition, the
elevated urinary PGE excretion suggests a role for prostaglan-
dins in mediating the "renal leak" seen in this patient. How-
ever, several points must be made concerning the use of non-
steroidal agents and assumptions concerning prostaglandin
mechanisms. These agents are not selective inhibitors of cyclo-
oxygenase and have multiple metabolic effects not associated
with prostaglandin metabolism [23, 60]. By using chemically
dissimilar agents in differing dosages, we have been able to
show a positive correlation between urinary PGE and calcium
excretion. This suggests that the correlation is between POE
and calcium excretion and not some nonspecific effect of the
nonsteroidal agents. As we did not measure other prostaglan-
dins, it is conceivable that another metabolite might be impli-
cated, although we feel that PGE is the most likely candidate
[48, 50, 601. POE is recognized to have an effect on sodium
transport [50] and has been shown to increase sodium and cal-
cium excretion in the dog [61, 621. Ben [63] has presented data
suggesting that prostaglandins, likely PGE [50, 52], inhibit the
hydro-osmotic effect of vasopressin by impairing cellular cal-
cium transport, a finding which may have relevance to the
hypercalciuria and polyuria seen in this patient.
Urinary calcium excretion in humans is influenced by many
factors, most of which are dietary [6, 64, 65]. Therefore, an in-
crease in dietary calcium, protein, sodium, or carbohydrate
will increase calcium excretion as will a diet deficient in phos-
phorus [64, 651. This is demonstrated in our patient who had a
significant decrease in urinary calcium excretion following in-
stitution of the diet with restricted sodium, calcium, and pro-
tein (Table 2). It is important to note that with this dietary
modification urinary PGE increased as urinary calcium fell,
demonstrating that PGE was not the only variable affecting re-
nal calcium excretion. Only when dietary considerations were
removed by utilizing a fixed diet were we able to show the re-
lationship between PGE and calcium excretion.
Not all patients with elevated PGE excretion have hyper-
calciuria. An example would be the typical patient with Bart-
ter syndrome where levels of PGE are high and hypercalciuria
is not a consistent finding [22, 26, 27, 66]. Similarly, dietary so-
dium restriction leads to a reduction in urinary calcium excre-
tion but an elevation in urinary PGE excretion [49, 50]. There-
fore, if PGE is a factor normally regulating urinary calcium ex-
cretion, it would appear to be interdependent with other
factors.
The implications of this study as related to the large number
of adult patients with idiopathic hypercalciuria is unclear, We
suggest that PGE may have a role in some cases of idiopathic
hypercalciuria, especially those associated with an apparent
"renal leak." Further studies are needed in this population to
address this question and to study the effects of prostaglandin
inhibition.
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